Objective-Patients with systemic lupus erythematosus are genetically predisposed to enhanced production of the type-I interferon IFN-α and are also at elevated risk of developing atherosclerosis compared with healthy subjects. We aimed to test whether genetic predisposition to increased type-I IFN production affects risk of coronary artery disease. Approach and Results-Using a list of 11 single nucleotide polymorphisms from the results of genome-wide association studies for systemic lupus erythematosus, which we hypothesised would be enriched in variants that regulate type-I IFN production, we identified a genetic risk score based on 3 single nucleotide polymorphisms (rs10516487, rs3131379 and rs7574865), which correlated significantly with production of IFN-α by human peripheral leukocytes stimulated with CpG-oligonucleotide (n=60, P=1.50×10 −5 ). These single nucleotide polymorphisms explained 27.8% of variation in the CpG-oligonucleotide-induced IFN-α response and were also associated with Toll-like receptor-7/8-and Toll-like receptor-9-dependent IFN-α and IFN-β responses, but were not associated with inflammatory cytokine production in response to Toll-like receptor-4 stimulation or risk of coronary artery disease in 22 233 cases and 64 762 controls (odds ratio 1.00, 95% CI 0.98-1.02) using Mendelian randomization-based analyses. Coronary artery disease risk was also not associated with the full panel of 11 systemic lupus erythematosus single nucleotide polymorphisms or loci responsible for the monogenic type-I interferonopathies Aicardi-Goutières syndrome and Spondyloenchondrodysplasia with immune dysregulation. Conclusions-The results argue against the potential utility of drugs targeting type-I IFN production for coronary artery disease.
A therosclerosis is a chronic inflammatory disease of the arteries that is regulated by cytokines of both the innate and adaptive immune systems. 1 Cytokines arising from the activation of the innate immune system may be broadly classified into either of 2 major types of response: the inflammatory response, which is characterized by hallmark proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, and the antiviral response, which is typified by production of type-I interferons (collectively, IFN-I). 2 The type-I IFNs comprise 13 IFN-α isotypes, IFN-β, IFNκ, IFN-ε, and IFN-ω, which are produced in response to the detection of conserved bacterial or viral nucleic acid motifs by intracellular pattern recognition receptors, such as endosomal Toll-like receptors (TLRs 3, 7, 8, or 9). 2 All IFN-I proteins signal through the shared type-I IFN receptor to upregulate expression of genes involved in antiviral defense. Much recent interest has been generated in the potential roles played by IFN-I in atherosclerosis because both pro-and antiatherogenic properties of IFN-I have been reported in murine models of the disease. [3] [4] [5] [6] [7] [8] Risk of coronary artery disease (CAD) is also markedly elevated in patients with the autoimmune disease systemic lupus erythematosus (SLE), which is thought to be driven largely by overproduction of IFN-α in genetically predisposed individuals. 9 A causal role for IFN-α in SLE is now widely accepted because serum IFN-α levels are significantly elevated in SLE patients in a manner that parallels disease activity and because therapeutic administration of IFN-α can induce SLElike symptoms that typically resolve on cessation of treatment. 10, 11 Serum IFN-α levels are also elevated in unaffected family members of SLE patients, suggesting that propensity to enhanced IFN-α production is heritable. 10 Supportive of this, it has been estimated that >50% of the loci identified in genome-wide association studies (GWAS) of SLE are proximal to genes involved in IFN-I production or signaling, 12 and leukocyte production of other cytokines has been shown to be highly heritable. 13 Crucially, the elevated risk of CAD in SLE patients (OR≈7.5) cannot be explained by traditional risk factors alone, raising further speculation that the increased risk of CAD in SLE may be because of IFN-I signaling. 9, 14 It has also been proposed that IFN-I may play a key role in atherogenesis in subjects without SLE because cumulative exposure to bacterial and viral infections (which systemically elevate IFN-I production) has been reported to be associated with CAD risk. 15 We therefore aimed to use a Mendelian randomization (MR)based approach to test whether propensity to IFN-I production is a causal risk factor for atherosclerosis in man. MR aims to define causal links between exposure and disease and is not generally susceptible to the reverse causation or confounding that may distort interpretations of conventional observational studies. 16 MR analyses use genetic variants as instruments for levels of a biomarker that may be part of a causal pathway for the disease of interest. However, as MR studies are dependent on the identification of genetic variants, which are strongly associated with the intermediate phenotype of interest, and because GWAS of leukocyte IFN-I production has not yet been performed, we hypothesized that genetic variants modifying the IFN-I response would be enriched in the results of GWAS for SLE and that these could be used to test causality of type-I IFN production with respect to risk of CAD by MR.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

Genetic Risk Score Based on 3 SLE Single Nucleotide Polymorphisms Correlates With Peripheral Blood Mononuclear Cell IFN-I Responses
To identify genetic variants with potential to regulate leukocyte IFN-I production, a list of 11 single nucleotide polymorphisms (SNPs) reported to be associated with SLE risk from 6 published reports of GWAS (or meta-analysis) for SLE, and 9 SNPs which have been reported to be associated with serum IFN-α levels in candidate gene studies of SLE, was collated ( Table 1 ; Table I in the online-only Data Supplement). [17] [18] [19] [20] [21] [22] Ingenuity TM pathway analysis confirmed that 8 of the 11 genes nearest to the SLE SNPs formed part of a network strongly connected to IFN-I production ( Figure I that regulate IFN-I responses. To assess the effect of these variants on the capacity of leukocytes to secrete IFN-I, peripheral blood mononuclear cells (PBMC) from 60 healthy volunteers (44 F, 16 mol/L, age 38.9±12.6 years) were challenged with established stimulants of IFN-I production: PolyI:C (a TLR3 stimulant), R848 (a TLR7/8 stimulant), and CpG-ODN-2216 (a TLR9 stimulant). Stepwise regression established that traditional risk factors for atherosclerosis (including age, sex, body mass index, diastolic blood pressure, systolic blood pressure, height, waist-to-hip ratio, smoking status, triglycerides, total cholesterol, LDL-cholesterol, or HDL-cholesterol) were not associated with PBMC IFN-α production.
Regression using the 20 candidate SNPs was then used to identify 3 SNPs that independently correlated with IFNα responses in the discovery group (n=34; rs10516487, P=0.0077; rs3131379, P=0.0304; rs7574865, P=0.0054; for details of cohorts, see Table II in the online-only Data Supplement). A genetic risk score (GRS) based on the sum of the IFN-I increasing alleles of these 3 SNPs was strongly associated with PBMC IFN-α responses in this cohort (β=872, 95% CI 530-1214, P=1.13×10 −5 ). These SNPs (and a further 2, rs729302 and rs3131379, which were close to statistical significance in the discovery cohort, P<0.09) were then genotyped in a replication cohort of 26 samples. The 3-SNP GRS was also significantly associated with IFN-α responses in this replication group (β=996, 95% CI 133-1859, P=0.025). A second round of regression revealed that rs10516487, rs3131379, and rs7574865 remained significantly correlated with IFN-α production in a combined analysis of the discovery and replication data (P=0.0083, 0.0118, and 0.0122, respectively), and the GRS based on these SNPs correlated significantly with CpG-ODN-induced IFN-α production (β=825, 95% CI 476-1175, P=1.50×10 −5 ; effect sizes summarized in Table III in the onlineonly Data Supplement), accounting for 27.8% of the variation in IFN-α production. Notably, the GRS was also positively associated with R848-induced IFN-α (P=0.002), R848-induced IFN-β (P=0.022), and CpG-ODN-induced IFN-β (P=0.027). Stratification of the results into GRS tertiles revealed that subjects in the highest GRS group produced significantly higher quantities of IFN-α and IFN-β in response to either R848 or CpG-ODN, compared with individuals in the lowest GRS group (Figure 1 , P<0.05). Taken together, these findings suggest that the variants identified by our screening strategy modulate not only IFN-α induced by TLR9 stimulation, but also IFN-α and IFN-β induced by other pathways, suggesting a key role for these loci in regulation of IFN-I production.
Inflammatory Cytokine Responses Do Not Correlate With Antiviral Cytokine Responses
Because innate immune signaling can result in either inflammatory or antiviral cytokine production, we next examined whether predisposition of individuals to production of antiviral cytokines correlated with production of inflammatory cytokines by the same subjects. PBMC from a third cohort of 32 healthy volunteers were challenged with an established inducer of IFN-I (CpG ODN) or inflammatory cytokine production (E. coli lipopolysaccharide [LPS]). Three cytokines typically associated with the inflammatory response (IL-1β, IL-6, and TNF-α) and 3 cytokines characteristic of the antiviral response (IFN-α, IFN-β, and CXCL-10) were then measured in supernatants at 24 h. The stimulants used were in the main very specific for their target cytokines, LPS inducing only IL-1β, IL-6 and TNF-α, while CpG ODN induced predominantly IFN-α, IFN-β and CXCL-10, but very little inflammatory cytokine production ( Figure 2A ). Although strong correlations were observed between LPS-induced IL-1β, IL-6, and TNF-α levels, these cytokines did not correlate well with CpG-ODN induction of IFN-α, IFN-β, and CXCL-10, which tended to cluster separately ( Figure 2B ). This suggests that individuals predisposed to elevated production of one type of inflammatory cytokine tend also to produce high levels of other inflammatory cytokines, but such predisposition is not correlated with production of IFN-I. Although the association of the GRS with CpG-induced IFN-α did not reach significance in this third cohort (P=0.1046), when combined with the results from the previous two cohorts, the GRS remained significantly associated with CpG-ODN-induced IFN-α production (β=521, 95% CI 234-807, P=5.23x10 −4 ) and was not significantly correlated with inflammatory cytokine production (P=0.610, 0.288, and 0.776 for LPS-induced IL-1β, IL-6, or TNF-α, respectively). 
Mendelian Randomization Analysis of Effects of IFN-I Regulating SNPs on CAD Risk
Having established a relationship between 3 SLE SNPs and IFN-I production, we next used these SNPs as instruments in an MR-based analysis to examine their effect on risk of CAD, using the effect sizes derived from the CpG-ODNinduced IFN-α ELISA results (Table III in the online-only Data Supplement). This analysis showed that the 3 SNPs had no effect, alone or combined, on CAD risk (pooled OR=1.00, 95% CI 0.98-1.02; Figure 3A ). Although no significant associations between rs10516487 or rs7574865 and established cardiovascular risk factors were identified after correction for multiple testing (Table 2) , there were small but significant effects of rs3131379 on total cholesterol (β=−0.05) and triglycerides (β=−0.04). However, as explained in Materials and Methods in the online-only Data Supplement, the effects of rs3131379 on CAD risk through total cholesterol and triglycerides were too small to have modified the conclusion, and repetition of the analysis with the omission of the pleiotropic SNP yielded the same results. To further validate these findings, we performed a MR analysis of all 11 SNPs reported to be associated with SLE in GWAS, using the odds ratio for SLE as the effect size. This also revealed no significant association of SLE SNPs with risk of CAD ( Figure 3B ; Table IV in the online-only Data Supplement). Power calculations using circulating IFN-α bioactivity as a proxy for leukocyte IFN-α production (the methods and limitations of which are discussed in Materials and Methods in the onlineonly Data Supplement) suggest that CARDIoGRAM has an estimated power of >95% at the 5% level of significance to detect the combined effect of the 2 nonpleiotropic SNPs on CAD through IFN-I. Taken together, these results suggest that genetic predisposition to leukocyte IFN-I production, or SLE risk, does not significantly alter risk of CAD in subjects without SLE.
Analysis of Loci Reported to be Associated With Monogenic Interferonopathies
To further explore the potential involvement of IFN-I regulating SNPs in CAD, we examined SNPs proximal (±500 kb) to 10 genes responsible for monogenic disorders of IFN-I overproduction (Aicardi-Goutières syndrome and Spondyloenchondrodysplasia with immune dysregulation) or deficiency in IFN-I production (UNC93B1 and TRAF3 deficiency). These loci do not overlap with loci previously identified in GWAS for CAD ( Table VI in 
Discussion
The question of whether IFN-I is a causal mediator of atherosclerosis in man is of much current interest because a variety of new drugs which inhibit IFN-I production or signaling are being developed for SLE. 23 To date, however, the potential utility of such drugs for CAD risk reduction remains unclear as both proand antiatherogenic properties of IFN-I have been reported in murine models of atherosclerosis. For example, IFN-α treatment was shown to accelerate plaque development in LDLR −/− mice, 3 whereas IFN-β accelerated collar-induced lesion formation and macrophage content of plaques in both ApoE −/− and LDLR −/− mice. 4 Likewise, reconstitution of LDLR −/− mice with myeloid cells lacking the IFN receptor reduced lesion development, potentially through inhibition of IFN-α-mediated priming of macrophage foam cell formation. 4, 5 In contrast, evidence has also been reported, which supports an antiatherogenic role of IFN-I. For example, the induction of systemic IFN-I production by TLR9 agonists reduced lesion severity in ApoE −/− mice 8 and IFN-β treatment reduced angiotensin-II-induced plaque formation in a carotid artery ligation model. 6 Accordingly, specific depletion of plasmacytoid dendritic cells, which are considered to be the principle source of circulating IFN-I in vivo, exacerbated lesion development in LDLR −/− mice. 7 Finally, although genetic deletion of pattern recognition receptors that lead mainly to inflammatory cytokine production reduces atherosclerosis in murine models (eg, TLR2 and TLR4), 24, 25 deficiency in pattern recognition receptors which are key inducers of IFN-I (such as TLR3, TLR7, or TLR9) has been reported to promote plaque formation in similar models. 8, 26, 27 To address this question with respect to atherosclerosis in man, we used genetic approaches which identified several new lines of evidence to suggest that IFN-I does not play a causal role for CAD in man. First, using leukocytes cultured ex vivo with defined stimuli, we identified 3 SNPs which were strongly associated with IFN-I production but which were not associated with inflammatory cytokine production or CAD risk. Second, 11 SNPs identified in GWAS for SLE, the majority of which are also likely to regulate IFN-α production or signaling, showed no association with CAD risk. Third, analysis of genomic regions proximal to 10 genes which are causal for several different forms of monogenic IFN-I deficiency or overproduction showed no association with CAD risk. These findings are in line with postmarketing reports that long-term use of recombinant IFN-β drugs for multiple sclerosis does not increase risk of CAD.
To further explore the potential involvement of this pathway in CAD and because SLE patients may be chronically exposed to IFN-inducing stimuli which are low or absent in the healthy CARDIoGRAM population, we also examined whether IFN-I regulating SNPs may modify CAD risk in SLE patients by performing pathway analysis of the 50 independent loci reported to be associated with CAD risk in SLE patients by Leonard et al. 28 Consistent with the earlier analyses, these pathways showed no relationship to IFN-I signaling ( Figure  IV in the online-only Data Supplement), and none of the IFN-I or SLE GWAS SNPs cited above were associated with risk of CAD in SLE patients. 28 Interestingly, 2 of the SNPs associated with CAD risk in SLE patients were identified near the IRF8 gene, 28 which play a key role in monocyte and B-cell differentiation, but may also contribute to IFN-I signaling. 12 However, the 2 IRF8 SNPs associated with CAD risk were not in linkage disequillibrium with those reported previously to be associated with risk of SLE itself or with SLE severity, which tracks serum IFN-α levels. Accordingly, the IRF8 SNPs which are associated with risk of SLE were not associated with CAD risk in SLE patients. 28 Together, these observations suggest that the IRF8 SNPs mediate their effect on CAD risk in SLE patients via mechanisms which are independent of IFN-I. These findings also add weight to the notion that a common mediator of distinct cellular responses (eg, inflammatory or antiviral responses) can be differentially regulated by distinct proximal SNPs (as explained in Figure V in the online-only Data Supplement). However, because the SLE population used for this analysis was relatively small (n=575), we should emphasize that the present analysis does not exclude the potential utility of drugs targeting IFN-I for the reduction of CAD risk in SLE patients.
The functional duality of IRF8 in this example also serves to illustrate one of the difficulties currently facing the investigation of potential mechanisms by which GWAS loci modify disease risk; namely that individual gene products often contribute to the regulation of multiple signaling pathways or cellular responses. We think that the technique we have described in this study, namely the identification of genetic variants that regulate responses of defined cell populations to specific stimuli for use in MR studies, should be a useful method to address these issues. Proof of concept of the discriminatory potential of the approach is evident in the finding that the IFN-I-regulating variants we identified were not associated with inflammatory cytokine production. It should also be noted, for this reason, that the results of the present study do not argue against a role for leukocyte responses to other stimuli, or production of other types of cytokine (particularly inflammatory cytokines), as potential causal mediators of CAD.
The method should also be particularly useful for the examination of causality of mediators which act locally, are shortlived, or are otherwise difficult to measure in plasma. In terms of specific applications, we are optimistic that this approach should have utility for investigations of causality of specific inflammatory signaling pathways in man, with potential to reveal useful therapeutic targets for CAD. Indeed, proinflammatory cytokine responses to LPS, for example, are highly heritable (eg, >80% for IL-1β) 13 and are associated with risk of atherosclerotic disease. [29] [30] [31] Although the identification of variants regulating such responses at the protein level by GWAS is likely to be challenging, 32 the recent identification of response quantitative trait loci through GWAS of gene transcription under conditions of specific stimuli has yielded promising results. 33, 34 Indeed, these studies have already indicated that many of the SNPs identified by GWAS for diverse diseases frequently overlap with response quantitative trait loci but not expression quantitative trait loci, and therefore the mechanisms underpinning the effects of such variants on disease are likely to be revealed only under condition of a particular stimulus. 33, 34 The findings from our study should be considered in the context of some limitations. First, we have examined IFN-I production and risk of CAD and SLE only in subjects of European ancestry, and the findings may not necessarily be applicable to other ethnicities. Second, our approach of identifying IFN-I regulating SNPs from a list of candidate variants identified from the SLE GWAS literature may have limited discovery of SNPs at other loci with potential to regulate IFN-I. Third, the effect-size estimates obtained for a response quantitative trait loci from in vitro stimulation studies may differ from the observed effect of the SNP in the general population. In terms of study power, we note that although our PBMC challenge trial is modestly sized (n=60), the SLE-SNP-based GRS was significantly correlated with response (P=1.50×10 −5 ) and explains 27.8% of variation in the CpG-ODN-induced IFN-α response. The use of a combination of SNPs, rather than a single SNP, as an instrument for MR has also been argued to increase the power and specificity of the analysis. 35 Finally, although we noted modest pleiotropy of rs3131379 in terms of blood cholesterol and triglycerides, analyses conducted with omission of this SNP yielded the same results. Moreover, these effects are unlikely to have confounded the findings because the effect sizes were too small to exert a significant effect on CAD risk given the available power.
In summary, we provide proof-of-concept that common genetic variants can be identified which regulate specific leukocyte signaling pathways and that these can be used as instruments in MR studies of human diseases. Our results suggest that genetic predisposition to leukocyte IFN-I production, or SLE risk, does not significantly alter risk of CAD in subjects without SLE. Further insight into the mechanisms by which genetic variants modify disease risk may benefit from the systematic identification of SNPs, which regulate induced cellular responses.
The autoimmune disease systemic lupus erythematosus is driven by genetic predisposition to overproduction of type-I interferons and is associated with a high incidence of atherosclerosis. As some mouse models have implicated type-I interferon production as a potential drug target for atherosclerosis and because drugs targeting type-I interferon production are being developed for systemic lupus erythematosus, we used stimulus-dependent single nucleotide polymorphisms discovery and a Mendelian randomization-based approach to test whether genetic variants which increase leukocyte type-I interferon production modify risk of coronary artery disease in man. The discovery that such variants are not associated with cardiovascular risk argues against the potential utility of drugs targeting type-I interferon production for coronary artery disease in man and validates the notion that single nucleotide polymorphisms may be discovered, which are specific for particular stimulus-dependent leukocyte signaling pathways. The approach we have described may therefore be extended to test potential causality of other candidate signaling pathways in human atherosclerosis.
Significance
